The Pharmalot View

The Pharmalot View By Ed Silverman

Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

The Pharmalot View By Ed Silverman

How a $37,000-a-year medicine sets a good model for drug pricing

The Pharmalot View By Ed Silverman

Here’s one drug safety rule the FDA should enact — quickly

The Pharmalot View By Ed Silverman

Dear Mr. President: Your view of the FDA is misguided. Here’s why

The Pharmalot View By Ed Silverman

Dear Vice President Pence: Stop peddling false hopes to dying patients

The Pharmalot View By Ed Silverman

Pharma trade group vows to review membership criteria, but is this an empty promise?

The Pharmalot View By Ed Silverman

Dear President Trump: Your big idea on drug pricing is half-baked

The Pharmalot View By Ed Silverman

Drug industry ad campaign may be too late to save its reputation

The Pharmalot View By Ed Silverman

Trump is considering a radical to lead FDA. That’s dangerous for public health

The Pharmalot View By Ed Silverman

Trump should be good medicine for the pharmaceutical industry. Here’s why

The Pharmalot View By Ed Silverman

Pharma may have defeated Prop 61, but state battles over pricing will continue

The Pharmalot View By Ed Silverman

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

The Pharmalot View By Ed Silverman

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

The Pharmalot View By Ed Silverman

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

The Pharmalot View By Ed Silverman

Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?

The Pharmalot View By Ed Silverman

The secretive system for vetting cancer drug use needs an urgent overhaul

The Pharmalot View By Ed Silverman

An open letter to Mylan CEO Heather Bresch about EpiPen pricing

The Pharmalot View By Ed Silverman

Laws to shed light on drug pricing strategies probably won’t work

The Pharmalot View By Ed Silverman

Pharma should not be allowed a loophole for reporting financial ties to docs

The Pharmalot View By Ed Silverman

The ‘gouge factor’: Big companies want transparency in drug price negotiations

The Pharmalot View By Ed Silverman

Pharma trade group says price gougers are outliers, but then accepts two more

The Pharmalot View By Ed Silverman

Pfizer wins big in opioid deal with Chicago. But what does the city get?

The Pharmalot View By Ed Silverman

Independence would be good for the FDA and the public

The Pharmalot View By Ed Silverman

Drug industry overstates impact of patent reviews on innovation

The Pharmalot View By Ed Silverman

Novartis, Colombia face off over cancer drug cost

The Pharmalot View By Ed Silverman

To get over sticker shock, new payment models are needed for gene therapies

The Pharmalot View By Ed Silverman

Cash prizes for pharma are needed to fight superbugs

The Pharmalot View By Ed Silverman

Why we shouldn’t trade a weakened FDA for more medical research funds

The Pharmalot View By Ed Silverman

Big drug maker presses for money-back guarantee that its science will work